JP2024521919A - ネオデグラダー－抗ｃｄ３３抗体コンジュゲート - Google Patents

ネオデグラダー－抗ｃｄ３３抗体コンジュゲート Download PDF

Info

Publication number
JP2024521919A
JP2024521919A JP2023574587A JP2023574587A JP2024521919A JP 2024521919 A JP2024521919 A JP 2024521919A JP 2023574587 A JP2023574587 A JP 2023574587A JP 2023574587 A JP2023574587 A JP 2023574587A JP 2024521919 A JP2024521919 A JP 2024521919A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521919A5 (enExample
Inventor
フィッシュキン，ネイサン
ユー パク，ピーター
バイ，チェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orum Therapeutics Inc
Bristol Myers Squibb Co
Original Assignee
Orum Therapeutics Inc
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orum Therapeutics Inc, Bristol Myers Squibb Co filed Critical Orum Therapeutics Inc
Publication of JP2024521919A publication Critical patent/JP2024521919A/ja
Publication of JP2024521919A5 publication Critical patent/JP2024521919A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023574587A 2021-06-03 2022-06-02 ネオデグラダー－抗ｃｄ３３抗体コンジュゲート Pending JP2024521919A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163202272P 2021-06-03 2021-06-03
US63/202,272 2021-06-03
US202163282588P 2021-11-23 2021-11-23
US63/282,588 2021-11-23
PCT/IB2022/055168 WO2022254377A1 (en) 2021-06-03 2022-06-02 Neodegrader-anti-cd33 antibody conjugates

Publications (2)

Publication Number Publication Date
JP2024521919A true JP2024521919A (ja) 2024-06-04
JP2024521919A5 JP2024521919A5 (enExample) 2025-06-09

Family

ID=84323935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574587A Pending JP2024521919A (ja) 2021-06-03 2022-06-02 ネオデグラダー－抗ｃｄ３３抗体コンジュゲート

Country Status (12)

Country Link
US (1) US20240252671A1 (enExample)
EP (1) EP4346910A4 (enExample)
JP (1) JP2024521919A (enExample)
KR (1) KR20240042598A (enExample)
AU (1) AU2022284372A1 (enExample)
CA (1) CA3222185A1 (enExample)
CL (2) CL2023003605A1 (enExample)
CO (1) CO2023016712A2 (enExample)
IL (1) IL308812A (enExample)
MX (1) MX2023014282A (enExample)
PE (1) PE20250159A1 (enExample)
WO (1) WO2022254377A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250090681A1 (en) * 2021-06-03 2025-03-20 Orum Therapeutics, Inc. Neodegrader conjugates
EP4527415A1 (en) * 2022-05-18 2025-03-26 Medilink Therapeutics (Suzhou) Co., Ltd. Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof
KR20250133786A (ko) * 2023-02-15 2025-09-08 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. 도마이드계 분자 접착제 유도체 및 이의 용도
WO2024222841A1 (zh) * 2023-04-27 2024-10-31 石药集团巨石生物制药有限公司 一种抗体药物偶联物
WO2024249235A1 (en) * 2023-06-01 2024-12-05 Abbvie Inc. Anti-human cd33 bet degrader antibody-drug conjugates
CN122422333A (zh) * 2023-10-17 2026-07-17 百时美施贵宝公司 Gspt1降解化合物、抗cd33抗体和抗体-药物缀合物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015515453A (ja) * 2012-03-03 2015-05-28 イミュンジーン，インコーポレーテッド 工学的に作製した抗体−インターフェロン変異体融合分子
JP2018516950A (ja) * 2015-06-12 2018-06-28 イミュンジーン, インコーポレイテッドImmunGene, Inc. がん治療のための集中インターフェロン免疫療法
JP2018518716A (ja) * 2015-06-30 2018-07-12 広東欧珀移動通信有限公司 撮像装置及びこの撮像装置を有する端末

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5238936B2 (ja) * 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
CA2957226C (en) * 2008-10-29 2018-08-14 Celgene Corporation Isoindoline compounds for use in the treatment of cancer
KR101870555B1 (ko) * 2011-08-23 2018-06-22 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
CN109152843A (zh) * 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
US20230338564A1 (en) * 2020-03-31 2023-10-26 Orum Therapeutics, Inc. Neodegrader conjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015515453A (ja) * 2012-03-03 2015-05-28 イミュンジーン，インコーポレーテッド 工学的に作製した抗体−インターフェロン変異体融合分子
JP2018516950A (ja) * 2015-06-12 2018-06-28 イミュンジーン, インコーポレイテッドImmunGene, Inc. がん治療のための集中インターフェロン免疫療法
JP2018518716A (ja) * 2015-06-30 2018-07-12 広東欧珀移動通信有限公司 撮像装置及びこの撮像装置を有する端末

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOMARKER RESEARCH, vol. 8:2, JPN6026013466, 2020, ISSN: 0005834651 *
BLOOD, vol. 137, no. 5, JPN6026013465, 4 February 2021 (2021-02-04), pages 661 - 677, ISSN: 0005834650 *

Also Published As

Publication number Publication date
CL2023003605A1 (es) 2024-05-03
PE20250159A1 (es) 2025-01-22
US20240252671A1 (en) 2024-08-01
CA3222185A1 (en) 2022-12-08
AU2022284372A9 (en) 2024-01-11
CL2026000399A1 (es) 2026-03-20
TW202313022A (zh) 2023-04-01
WO2022254377A1 (en) 2022-12-08
EP4346910A1 (en) 2024-04-10
CO2023016712A2 (es) 2024-02-26
KR20240042598A (ko) 2024-04-02
MX2023014282A (es) 2024-02-27
IL308812A (en) 2024-01-01
EP4346910A4 (en) 2026-05-06
AU2022284372A1 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
JP7735526B2 (ja) リンカー、薬物リンカーおよびそのコンジュゲートならびにそれらの使用方法
US20240252671A1 (en) Neodegrader-anti-cd33 antibody conjugates
JP2023519974A (ja) ｎｅｏＤｅｇｒａｄｅｒコンジュゲート
JP7573685B2 (ja) 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用
CN113929738B (zh) 抗体-药物偶联物
CA3231039A1 (en) Linkers for use in antibody drug conjugates
CN118201641A (zh) 新降解剂－抗cd33抗体缀合物
KR20230154892A (ko) 항-her2 항체-약물 접합체 및 이의 용도
KR20210106467A (ko) 튜불리신 및 단백질-튜불리신 접합체
CN120456929A (zh) Cd70抗体药物缀合物及其使用方法
US20250304563A1 (en) Activators of effector t cells
KR20250130409A (ko) 링커, 약물 링커 및 그의 접합체 및 그의 사용 방법
JP2024059856A (ja) 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用
TW202423411A (zh) 新降解劑綴合物
EA051016B1 (ru) Конъюгаты неодеградер-анти-cd33 антитело
RU2846388C1 (ru) Конъюгаты неодеструкторов
WO2026069278A1 (en) Anti-cd123 antibodies and neodegrader conjugates

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260609